News

  • 11 February 2019

    Genkyotex (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced today that Professor Gareth Thomas of the University of Southampton, United Kingdom (UK), was awarded a Biotherapeutics Drug Discovery Project grant by Cancer Research UK (CRUK), a leading cancer research and awareness organization based in the UK, to conduct a research program focused on the role of NOX inhibition in oncology. The £260 thousand grant will support the research program entitled "Combination immunotherapy for breast cancer: targeting cancer-associated fibroblasts to improving therapeutic vaccination.” This is the second grant provided by CRUK to Professor Thomas for the evaluation of NOX inhibitors in oncology. 

  • 8 February 2019

    Sequana Medical NV - ("Sequana Medical", the "Company"), a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, today announces the results of its initial public offering of new shares, with the admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol "SEQUA", launched on 31 January 2019 (the "Offering").

  • 31 January 2019

    Genkyotex (Euronext Paris & Brussels: FR0011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, today provided a corporate update, and reported cash and cash equivalents of €10.2 million, at December 31st , 2018.

  • 15 January 2019

    JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive John T. Kilcoyne as Chief Executive Officer, effective immediately. In addition, he will serve as a member of the Board of Directors.

  • 4 January 2019

    Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that Bahija Jallal has been appointed as Chief Executive Officer and Director of the Board.